Answers are grounded in this paper and cite their sources.
Treatment of hepatocellular carcinoma (HCC) using adoptive cell therapy is still challenging because of the heterogeneity of antigens expressed on tumor cells and highly suppressive liver microenvironment. Glypican-3 (GPC3) has been identified as one of the most promising therapeutic targets as it is highly expressed in HCC cells but has low expression in normal adult liver tissue. Over the past few years, natural killer (NK) cells have emerged as a promising platform for chimeric antigen receptor (CAR) engineering. Compared with CAR-T cells, CAR-NK cells can be used in allogeneic settings and are generally associated with lower inflammatory toxicity. Advanced CAR technologies, including improved antigen-binding domains and NK-specific signaling domains such as DAP10, DAP12, and 2B4, have enhanced NK-cell activation and cytotoxic activity. Cytokine support systems like IL-15 and IL-21, along with synthetic biology approaches such as hypoxia-responsive systems and logic-gated receptors, are being explored to improve the performance of CAR-NK cells. However, challenges such as immunosuppressive signaling, metabolic stress, and limited immune-cell infiltration in the hepatic tumor microenvironment still need to be addressed. This review discusses recent advances in the development of GPC3-targeted CAR-NK therapies and highlights strategies that may improve their therapeutic potential in HCC.
No takes yet. Share an insight, caveat, or question.
Hattiwale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: